Having trouble accessing articles? Reset your cache.

Pradaxa dabigatran etexilate regulatory update

FDA updated the label of Pradaxa dabigatran etexilate from Boehringer to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)

Read the full 263 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE